Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 894,505
  • Shares Outstanding, K 190,726
  • Annual Sales, $ 0 K
  • Annual Income, $ -355,930 K
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.59
Trade SANA with:

Options Overview Details

View History
  • Implied Volatility 104.39% ( +12.12%)
  • Historical Volatility 91.78%
  • IV Percentile 59%
  • IV Rank 31.78%
  • IV High 261.93% on 12/29/22
  • IV Low 31.00% on 10/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 644
  • Open Int (30-Day) 855

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.41
  • Number of Estimates 1
  • High Estimate -0.41
  • Low Estimate -0.41
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +36.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.15 +46.31%
on 12/28/22
4.88 -5.53%
on 01/17/23
+1.22 (+35.99%)
since 12/23/22
3-Month
3.15 +46.31%
on 12/28/22
6.31 -26.94%
on 11/15/22
-1.17 (-20.24%)
since 10/26/22
52-Week
3.15 +46.31%
on 12/28/22
9.60 -51.98%
on 04/12/22
-3.49 (-43.09%)
since 01/26/22

Most Recent Stories

More News
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2781 (+3.50%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2781 (+3.50%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
4 Downgraded Stocks You'll Want to Sell or Avoid Right Now

With the growing odds of the economy tipping into a recession due to an aggressive monetary policy tightening to tame the sky-high inflation, it could be difficult for fundamentally weak stocks to stay...

IVZ : 18.47 (+2.61%)
KYMR : 35.48 (-3.51%)
MOGO : 0.7501 (+0.93%)
SANA : 4.61 (-1.71%)
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent...

SANA : 4.61 (-1.71%)
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented...

SANA : 4.61 (-1.71%)
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as...

SANA : 4.61 (-1.71%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2781 (+3.50%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines

Flagship Pioneering, the bioplatform innovation company, today unveiled ProFound™ Therapeutics, a company that has identified a universe of previously undiscovered human proteins, enabling a multitude...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2781 (+3.50%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as...

SANA : 4.61 (-1.71%)
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file...

SANA : 4.61 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.98
1st Resistance Point 4.80
Last Price 4.61
1st Support Level 4.44
2nd Support Level 4.26
3rd Support Level 4.08

See More

52-Week High 9.60
Fibonacci 61.8% 7.14
Fibonacci 50% 6.38
Fibonacci 38.2% 5.61
Last Price 4.61
52-Week Low 3.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar